Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma

Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, r...

Full description

Saved in:
Bibliographic Details
Published in:Neurohospitalist 2018-10, Vol.8 (4), p.191-193
Main Authors: Baird-Gunning, Jonathan J. D., Weerasinghe, Dinushi, Silsby, Matthew, Gawarikar, Yash, Carlino, Matteo S., Smith, Jessica L., Vucic, Steve
Format: Article
Language:English
Subjects:
Case Reports
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, resulting in upregulation of the host immune response to cancer cells. There is increasing recognition of immune-mediated adverse events associated with immune therapies in patients with cancer. We present a case report of a patient who developed Miller Fisher syndrome associated with these therapies for metastatic melanoma along with a discussion of its management.
ISSN:1941-8744
1941-8752
DOI:10.1177/1941874418778957